Sionna Therapeutics Reports Q3 2026 Financial Results; Net Loss of $32.4M
Sionna Therapeutics reported a Q3 2026 net loss of $32.4 million, or $(0.72) per share, compared to a net loss of $20.3 million, or $(0.46) per share, in Q3 2025. Research and development expenses increased to $22.0 million from $16.0 million year-over-year, while general and administrative expenses rose to $12.8 million from $7.8 million. The company ended the quarter with $249.8 million in cash and cash equivalents, which it expects to fund operations into the second half of 2029.
Read source-backed brief